Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set

Clinical Gastroenterology and Hepatology

Volumn 16, Issue 5, 2018, Pages 637-647.e13

  Ma, Christopher ^a   Panaccione, Remo ^a   Fedorak, Richard N ^b   Parker, Claire E ^c   Nguyen, Tran M ^c   Khanna, Reena ^c,d   Siegel, Corey A ^e   Peyrin Biroulet, Laurent ^f   D'Haens, Geert ^c,g   Sandborn, William J ^c,h   Feagan, Brian G ^c,d   Jairath, Vipul ^c,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

COS; IBD; MCS; RCT; UCDAI

Indexed keywords

AMINOSALICYLIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; LACTOFERRIN; GASTROINTESTINAL AGENT;

DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FECES LEVEL; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HISTOLOGY; HUMAN; INFECTION; INFUSION RELATED REACTION; PATIENT-REPORTED OUTCOME; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REMISSION; REVIEW; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; PATHOLOGY; TREATMENT OUTCOME;

COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85041613803     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2017.08.025     Document Type: Review

References (92)

1. Truelove, S.C., Witts, L.J., Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 2 (1955), 1041–1048.
2. Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
3. Williet, N., Sandborn, W.J., Peyrin-Biroulet, L., Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 12 (2014), 1246–1256.e6.
4. Ma, C., Panaccione, R., Fedorak, R.N., et al. Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open, 7, 2017, e016146.
5. Williamson, P.R., Altman, D.G., Blazeby, J.M., et al. Developing core outcome sets for clinical trials: issues to consider. Trials, 13, 2012, 132.
6. Schroeder, K.W., Tremaine, W.J., Ilstrup, D.M., Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317 (1987), 1625–1629.
7. Sutherland, L.R., Martin, F., Greer, S., 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92 (1987), 1894–1898.
8. Sutherland, L.R., Martin, F., 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci 32:12 Suppl (1987), 64S–66S.
9. Williams, C.N., Haber, G., Aquino, J.A., Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories. Dig Dis Sci 32:12 Suppl (1987), 71S–75S.
10. Sutherland, L.R., Robinson, M., Onstad, G., et al. A ddouble-blind placebo controlled, multicentre study of the efficiacy and safety of 5-aminosalicylic acid tables in the treatment of ulcerative colitis. Can J Gastroenterol 4 (1990), 463–467.
11. Sninsky, C.A., Cort, D.H., Shanahan, F., et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 115 (1991), 350–355.
12. Sandborn, W.J., Tremaine, W.J., Schroeder, K.W., et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 106 (1994), 1429–1435.
13. Oren, R., Arber, N., Odes, S., et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110 (1996), 1416–1421.
14. Steinhart, A.H., Hiruki, T., Brzezinski, A., et al. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 10 (1996), 729–736.
15. Beeken, W., Howard, D., Bigelow, J., et al. Controlled trial of 4-ASA in ulcerative colitis. Dig Dis Sci 42 (1997), 354–358.
16. Feagan, B.G., McDonald, J., Greenberg, G., et al. An ascending dose trial of a humanized A4 B7 antibody in ulcerative colitis (UC). Gastroenterology, 118, 2000, A874.
17. Nikolaus, S., Rutgeerts, P., Fedorak, R., et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 52 (2003), 1286–1290.
18. Probert, C.S., Hearing, S.D., Schreiber, S., et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52 (2003), 998–1002.
19. Sandborn, W.J., Sands, B.E., Wolf, D.C., et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 17 (2003), 1355–1364.
20. van Deventer, S.J., Tami, J.A., Wedel, M.K., A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 53 (2004), 1646–1651.
21. Feagan, B.G., Greenberg, G.R., Wild, G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352 (2005), 2499–2507.
22. Marteau, P., Probert, C.S., Lindgren, S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54 (2005), 960–965.
23. Rutgeerts, P., Sandborn, W.J., Feagan, B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005), 2462–2476.
24. van Deventer, S.J., Wedel, M.K., Baker, B.F., et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 23 (2006), 1415–1425.
25. Ogata, H., Matsui, T., Nakamura, M., et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55 (2006), 1255–1262.
26. Van Assche, G., Sandborn, W.J., Feagan, B.G., et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55 (2006), 1568–1574.
27. Kamm, M.A., Sandborn, W.J., Gassull, M., et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132 (2007), 66–75 quiz 432–433.
28. Lichtenstein, G.R., Kamm, M.A., Boddu, P., et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 5 (2007), 95–102.
29. Schreiber, S., Keshavarzian, A., Isaacs, K.L., et al. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 132 (2007), 76–86.
30. Lewis, J.D., Lichtenstein, G.R., Deren, J.J., et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134 (2008), 688–695.
31. Scherl, E.J., Pruitt, R., Gordon, G.L., et al. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 104 (2009), 1452–1459.
32. Leiper, K., Martin, K., Ellis, A., et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 60 (2011), 1520–1526.
33. Reinisch, W., Sandborn, W.J., Hommes, D.W., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60 (2011), 780–787.
34. Vermeire, S., Ghosh, S., Panes, J., et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 60 (2011), 1068–1075.
35. Ogata, H., Kato, J., Hirai, F., et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 18 (2012), 803–808.
36. Sandborn, W.J., van Assche, G., Reinisch, W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142 (2012), 257–265 e1–e3.
37. Sandborn, W.J., Travis, S., Moro, L., et al. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 143 (2012), 1218–1226 e1–e2.
38. Sandborn, W.J., Colombel, J.F., Sands, B.E., et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 143 (2012), 62–69.e4.
39. Sandborn, W.J., Ghosh, S., Panes, J., et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367 (2012), 616–624.
40. Sands, B.E., Sandborn, W.J., Creed, T.J., et al. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology 143 (2012), 356–364.e1.
41. Feagan, B.G., Rutgeerts, P., Sands, B.E., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369 (2013), 699–710.
42. Feagan, B.G., Sandborn, W.J., D'Haens, G., et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 145 (2013), 149–157.e2.
43. Rutgeerts, P.J., Fedorak, R.N., Hommes, D.W., et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 62 (2013), 1122–1130.
44. Watanabe, M., Nishino, H., Sameshima, Y., et al. Randomised clinical trial: Evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - A placebo-controlled study. Aliment Pharmacol Ther 38 (2013), 264–273.
45. Mayer, L., Sandborn, W.J., Stepanov, Y., et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut 63 (2014), 442–450.
46. Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 85–95 quiz e14–e15.
47. Suzuki, Y., Motoya, S., Hanai, H., et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 49 (2014), 283–294.
48. Travis, S.P., Danese, S., Kupcinskas, L., et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 63 (2014), 433–441.
49. Vermeire, S., O'Byrne, S., Keir, M., et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 384 (2014), 309–318.
50. Danese, S., Rudzinski, J., Brandt, W., et al. Tralokinumab for moderate-to-severe UC: A randomised, double-blind, placebo-controlled, phase IIa study. Gut 64 (2015), 243–249.
51. Jiang, X.L., Cui, H.F., Gao, J., et al. Low-dose infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis. J Clin Gastroenterol 49 (2015), 582–588.
52. Pontes, C., Vives, R., Torres, F., et al. Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflamm Bowel Dis 20 (2015), 2004–2012.
53. Reinisch, W., Panes, J., Khurana, S., et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: Efficacy and safety from a phase IIa randomised multicentre study. Gut 64 (2015), 894–900.
54. Reinisch, W., Sandborn, W., Danese, S., et al. A randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis: results of the turandot study. Gastroenterology, 148(4 Suppl 1), 2015, S1193.
55. Rubin, D.T., Cohen, R.D., Sandborn, W.J., et al. Budesonide MMX 9 mg for inducing remission in patients with Mild-to-Moderate ulcerative colitis not adequately controlled with oral 5-ASAs. J Crohn's Colitis, 9, 2015, S7.
56. Rutgeerts, P., Feagan, B.G., Marano, C.W., et al. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther 42 (2015), 504–514.
57. Sandborn, W.J., Bosworth, B., Zakko, S., et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology 148 (2015), 740–750.e2.
58. Suzuki, Y., Motoya, S., Hirai, F., et al. Infliximab therapy for Japanese patients with ulcerative colitis: Efficacy, safety, and association between serum infliximab levels and early response in a randomized, double-blind, placebo-controlled study. J Crohn's Colitis 9 (2015), S372–S373.
59. Yoshimura, N., Watanabe, M., Motoya, S., et al. Safety and efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology 149 (2015), 1775–1783.e2.
60. Atreya, R., Bloom, S., Scaldaferri, F., et al. Clinical effects of a topically applied toll-like receptor 9 agonist in active moderate-to-severe ulcerative colitis. J Crohn's Colitis 10 (2016), 1294–1302.
61. Carbonnel, F., Colombel, J.F., Filippi, J., et al. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology 150 (2016), 380–388.e4.
62. Harris, M.S., Hartman, D., Lemos, B.R., et al. AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial. J Crohn's Colitis 10 (2016), 631–640.
63. Naganuma, M., Aoyama, N., Suzuki, Y., et al. Twice-daily budesonide 2-mg foam induces complete mucosal healing in patients with distal ulcerative colitis. J Crohn's Colitis 10 (2016), 828–836.
64. Sandborn, W.J., Colombel, J.F., Ghosh, S., et al. Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: A randomised, placebo-controlled, phase 2b study. J Crohn's Colitis 10 (2016), 418–428.
65. Sandborn, W.J., Feagan, B.G., Wolf, D.C., et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 374 (2016), 1754–1762.
66. Sandborn, W., Sands, B.E., D'Haens, G.R., et al. Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials. Gastroenterology, 1, 2016, S157.
67. Sandborn, W.J., Bhandari, B.R., Fogel, R., et al. Randomised clinical trial: A phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther 44 (2016), 157–169.
68. Van Assche, G., Rutgeerts, P., Ferrante, M., et al. Safety and efficacy of a novel IV targeted pegylated liposomal prednisolone product (Nanocort): results from a phase 2a study in patients with active ulcerative colitis. J Crohn's Colitis 10 (2016), S39–S40.
69. Kucharzik, T., Lemmnitz, G., Abels, C., et al. Tripeptide K(D)PT is well tolerated in mild-to-moderate ulcerative colitis: results from a randomized multicenter study. Inflamm Bowel Dis 23 (2017), 261–271.
70. Hanauer, S., Good, L.I., Goodman, M.W., et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 95 (2000), 1749–1754.
71. Lichtenstein, G.R., Gordon, G.L., Zakko, S., et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. Aliment Pharmacol Ther 32 (2010), 990–999.
72. Sandborn, W.J., Danese, S., Ballard, E.D., et al. Efficacy of budesonide MMx(r) 6 mg QD for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study. Gastroenterology, 142, 2012, S-564.
73. Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 96–109.e1.
74. Gordon, G.L., Zakko, S., Murthy, U., et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis: a randomized, placebo-controlled clinical trial. J Clin Gastroenterol 50 (2016), 318–325.
75. Jairath, V., Khanna, R., Zou, G.Y., et al. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther 42 (2015), 1200–1210.
76. Kim, J.H., Cheon, J.H., Park, Y., et al. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Scand J Gastroenterol 51 (2016), 1069–1074.
77. U.S. Food and Drug Administration. Ulcerative Colitis: Clinical Trial Endpoints Guidance for Industry 2016. Available at: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM515143.pdf. Accessed May 25, 2017.
78. Christensen, B., Hanauer, S.B., Erlich, J., et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol 15 (2017), 1557–1564.
79. De Vos, M., Louis, E.J., Jahnsen, J., et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 19 (2013), 2111–2117.
80. Colombel, J.F., Panaccione, R., Bossuyt, P., et al. Superior endoscopic and deep remission outcomes in adults with moderate to severe Crohn's Disease managed with treat to target approach versus clinical symptoms: data from calm. Gastroenterology, 152, 2017, S155.
81. Lichtenstein, G.R., Feagan, B.G., Cohen, R.D., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 (2006), 621–630.
82. Chapman, R.W., Selby, W.S., Jewell, D.P., Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27 (1986), 1210–1212.
83. Mantzaris, G.J., Hatzis, A., Kontogiannis, P., et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 89 (1994), 43–46.
84. Turunen, U.M., Farkkila, M.A., Hakala, K., et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 115 (1998), 1072–1078.
85. Petersen, A.M., Mirsepasi, H., Halkjaer, S.I., et al. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis 8 (2014), 1498–1505.
86. Kruis, W., Fric, P., Pokrotnieks, J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004), 1617–1623.
87. Gionchetti, P., Rizzello, F., Ferrieri, A., et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 44 (1999), 1220–1221.
88. Miele, E., Pascarella, F., Giannetti, E., et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104 (2009), 437–443.
89. Sood, A., Midha, V., Makharia, G.K., et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7 (2009), 1202–1209 1209.e1.
90. D'Haens, G., Sandborn, W.J., Feagan, B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132 (2007), 763–786.
91. Bodger, K., Ormerod, C., Shackcloth, D., et al. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut 63 (2014), 1092–1102.
92. Marchal-Bressenot, A., Salleron, J., Boulagnon-Rombi, C., et al. Development and validation of the Nancy histological index for UC. Gut 66 (2017), 43–49.